Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield) and/or Sinopharm, BBIBP-CorV (Vero cell)

CONCLUSIONS: The humoral response was higher among HCPs who received two-doses vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™) vaccine, and among those with six or more months of elapse of vaccination. The seroprevalence of SARS-CoV-2 following two-doses vaccination among HCPs was more than nine-tenths.PMID:38615227 | DOI:10.33314/jnhrc.v21i3.4634
Source: Cell Research - Category: Cytology Authors: Source Type: research